SCHEMBL20920148

SCHEMBL20920148

O=C(NC1CCOCC1)c1cc(Cc2ccc(-n3cccn3)cc2)c2cccnn12

nearest known ligand 0.61

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 19/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20929434 0.83 CHRM1 (0.65) CHRM1
SCHEMBL21875394 0.82 CHRM1 (0.49) CHRM1
SCHEMBL20917726 0.82 CHRM1 (0.46) CHRM1
SCHEMBL30179239 0.82 CHRM1 (0.46) CHRM1
SCHEMBL17440113 0.79 CHRM1 (0.78) CHRM1
SCHEMBL21878466 0.77 CHRM1 (0.54) CHRM1
SCHEMBL18027674 0.77 CHRM1 (0.80) CHRM1
SCHEMBL21936387 0.77 CHRM1 (0.53) CHRM1
SCHEMBL24031167 0.76 CHRM1 (0.50) CHRM1
SCHEMBL21878465 0.76 CHRM1 (0.57) CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111212840-B Heteroaryl compounds as positive allosteric modulators of the muscarinic M1 receptor 苏文生命科学有限公司 2022-07-22 CN claimed
EP-3697790-A1 HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS Suven Life Sciences Limited (IN) 2020-08-26 EP claimed
CN-111212840-A Heteroaryl compounds as positive allosteric modulators of the muscarinic M1 receptor 苏文生命科学有限公司 2020-05-29 CN claimed
WO-2019077517-A1 HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS SUVEN LIFE SCIENCES LIMITED (IN) 2019-04-25 WO claimed
EP-3697790-B1 HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS SUVEN LIFE SCIENCES LTD (IN) 2023-01-18 EP disclosed
CN-111212840-B Heteroaryl compounds as positive allosteric modulators of the muscarinic M1 receptor 苏文生命科学有限公司 2022-07-22 CN disclosed
US-11234979-B2 Heteroaryl compounds as muscarinic M1 receptor positive allosteric modulators SUVEN LIFE SCIENCES LIMITED (IN) 2022-02-01 US disclosed
US-20200237761-A1 HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS SUVEN LIFE SCIENCES LIMITED (IN) 2020-07-30 US disclosed
CN-111212840-A Heteroaryl compounds as positive allosteric modulators of the muscarinic M1 receptor 苏文生命科学有限公司 2020-05-29 CN disclosed
WO-2019077517-A1 HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS SUVEN LIFE SCIENCES LIMITED (IN) 2019-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200237761-A1 HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS CHRM1, CHRM2, CHRM3 CHRM1 1/4885
US-11234979-B2 Heteroaryl compounds as muscarinic M1 receptor positive allosteric modulators CHRM1, CHRM2, CHRM3 CHRM1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.